The Treatment of Acute Leukaemia with 6-Mercaptopurine
The recently introduced purine antimetabolite, 6-mercaptopurine, has been in clinical therapeutic trials in acute leukaemia at several centres in the last three years. The reports of such authors as Burchenal et al (1953), Hall et al (1954), Fountain (1955), and our own earlier experience (Hayhoe and Whitby 1955) have demonstrated that this substance is of potential value in three chief respects.
Unable to display preview. Download preview PDF.
- Burchenal, J. H., M. L. Murphy, R. R. Ellison, M. P. Sykes, T. C. Tan, L. A. Leone, D. A. Karnofsky, L. F. Craver, H. W. Dargeon, and C. P. Rhoads: Clinical evaluation of a new antimetabolite, 6-mercaptopurine in the treatment of leukaemia and allied diseases. Blood 8, 965–999 (1953).PubMedGoogle Scholar